Outpace Bio, a Leader in Protein Design for Cell Therapy, Announces Presentation at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
09 mai 2023 09h00 HE
|
Outpace Bio
Seattle, WA, May 09, 2023 (GLOBE NEWSWIRE) -- Outpace Bio, a company using protein design and cell engineering to create advanced cell therapies with curative potential, today announced that an...
Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology
09 mai 2023 07h30 HE
|
Adaptive Biotechnologies
SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Celyad Oncology reports first quarter 2023 financial results and recent business highlights
05 mai 2023 01h00 HE
|
Celyad Oncology SA
Presentation of updated data on our multiplex shRNA platform, which allows targeting of up to four genes simultaneouslyPublication of results from the THINK trial, which provided proof-of-concept of...
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023
04 mai 2023 16h05 HE
|
Lyell Immunopharma, Inc
Two phase 1 clinical trials recruiting patients at 14 sites across the US; nine sites for LYL797, a ROR-1-targeted chimeric antigen receptor T cell (CAR-T) product candidate, and five sites for...
Outpace Bio, a Leader in Protein Design for Cell Therapy, Strengthens Executive Leadership Team with Key Appointments
04 mai 2023 08h00 HE
|
Outpace Bio
Seattle, WA, May 04, 2023 (GLOBE NEWSWIRE) -- Outpace Bio, a company using protein design and cell engineering to create advanced cell therapies, today announced two key leadership appointments....
Immatics veröffentlicht klinisches Daten-Update aus laufender Phase-1b-Zelltherapie-Studie mit ACTengine® IMA203 TCR-T-Monotherapie in Kohorte A gegen die Zielstruktur PRAME
02 mai 2023 07h00 HE
|
Immatics N.V.
Live-Webcast am Dienstag, den 2. Mai, um 14:30 Uhr MESZ Update umfasst Daten von 11 stark vorbehandelten Patienten nach Letztlinientherapie in der Phase-1b-Dosisexpansionskohorte A, die mit der...
Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME
02 mai 2023 07h00 HE
|
https://immatics.com/
Company to host conference call today, May 2, at 8:30 am EDT / 2:30 pm CEST Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203...
Immatics gibt erstes Opt-in von Bristol Myers Squibb für TCR-T-Zelltherapiekandidaten aus aktueller strategischer Multi-Target-Kollaboration bekannt
01 mai 2023 07h00 HE
|
Immatics N.V.
Bristol Myers Squibb hat die erste Option in Anspruch genommen und eine globale Lizenzvereinbarung mit Immatics für den ersten TCR-T-Zelltherapie-Produktkandidaten abgeschlossen; die bestehende...
Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration
01 mai 2023 07h00 HE
|
https://immatics.com/
Bristol Myers Squibb exercised its first option and entered into a global license agreement with Immatics for the most advanced TCR-T product candidate from the companies’ ongoing collaboration to...
Global Digital Biomanufacturing Market Report 2023: Growing Number of Biologics-related Clinical Trials Fuels the Sector
01 mai 2023 04h58 HE
|
Research and Markets
Dublin, May 01, 2023 (GLOBE NEWSWIRE) -- The "Digital Biomanufacturing Market - Distribution by Type of Technology, Deployment Options, Types of Biologics Manufactured, and Key Geographical Regions:...